Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.

ABSTRACT:

Background and objectives

Hepatitis C virus infection is common in patients with CKD and leads to accelerated progression to ESRD. Sofosbuvir is a potent direct-acting antiviral therapy against hepatitis C virus; however, there are concerns about its safety in patients with CKD. The objective of our study was to determine the safety and efficacy of sofosbuvir in patients with CKD.

Design, setting, participants, & measurements

We studied a retrospective observational cohort of patients with CKD defined by eGFR<60 ml/min per 1.73 m², ≥30 mg albuminuria per 1 g creatinine, or ≥200 mg proteinuria per 1 g creatinine who received sofosbuvir-based therapy in a large health care system. Regression models were constructed to predict likelihood of sustained virologic respon

SUBMITTER: Sise ME 

PROVIDER: S-EPMC5628711 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature